Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue.
PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
Unspecified Adult Solid Tumor, Protocol Specific
Radiation: stereotactic radiosurgery
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors|
|Study Start Date:||February 1999|
|Study Completion Date:||November 2004|
|Primary Completion Date:||November 2004 (Final data collection date for primary outcome measure)|
- Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors.
- Assess the toxicities of this treatment regimen in these patients.
- Determine tumor response and cause of death in these patients treated with this regimen.
OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006456
|United States, Virginia|
|Massey Cancer Center|
|Richmond, Virginia, United States, 23298-0058|
|Study Chair:||Danny Y. Song, MD||Massey Cancer Center|